Registry of adult patients with atrial fibrillation in China
Official title: Chinese Atrial Fibrillation Registry
Run by Beijing Anzhen Hospital · NCT06987825 · Data updated 2026-11-12
This study is creating a long-term registry of adults with atrial fibrillation in China to see how different treatments work and how they affect patients' lives.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100000 (estimated) |
| Sponsor | Beijing Anzhen Hospital Academic / other |
| Locations | 2 sites (Beijing, Beijing Municipality and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2011 |
| Main results expected | December 31, 2035 |
| Study ends | December 31, 2035 |
| Registry record updated | May 23, 2025 |
| Trial ID | NCT06987825 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with documented atrial fibrillation episodes lasting more than 30 seconds.
✕Probably not a fit
Patients with atrial fibrillation due to reversible causes or those with comorbid conditions limiting life expectancy to less than one year may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This prospective, observational cohort study aims to create a long-term registry of adult patients with atrial fibrillation (AF) in China. It will collect standardized clinical data from over 30 hospitals to characterize patient profiles and evaluate real-world management and outcomes. The study will assess the effectiveness and safety of various AF treatment strategies and identify factors influencing therapeutic outcomes. Participants will undergo regular follow-ups to monitor heart rhythm, treatment updates, and quality of life assessments.
Why it matters
Potential benefit: If successful, this registry could enhance the understanding and management of atrial fibrillation, leading to improved patient outcomes.
How similar studies have gone: Other observational registries have shown success in improving understanding and management of atrial fibrillation, making this approach both relevant and tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. Documented atrial fibrillation episode lasting \>30 seconds confirmed by electrocardiogram (ECG), Holter monitor, implantable cardiac monitor, or wearable ECG device 3. Signed informed consent and willingness to participate in follow-up Exclusion Criteria: 1. Atrial fibrillation due to a reversible cause (e.g., transient secondary AF) 2. Presence of comorbid conditions associated with an expected life expectancy of less than 1 year
Where it's running
-
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China Recruiting -
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Changsheng Ma, MD — Beijing Anzhen Hospital
- Study coordinator: Liu He, PhD
- Email: theliu@139.com
- Phone: +86 13810720787
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulsed Field vs Cryoballoon for Pulmonary Vein Isolation in Atrial Fibrillation
This trial tests whether pulsed field ablation can shorten the procedure for first-time PVI in AF patients compared with cryoballoon ablation, while keeping safety and effectiveness similar.
-
Pulsed Field Ablation vs Cryoablation for Atrial Fibrillation Under Deep Sedation
This trial tests whether pulsed field ablation (PFA) done under deep sedation works as well as cryoballoon ablation for treating atrial fibrillation, aiming to avoid general anesthesia.
-
Bachmann’s Bundle Pacing vs Right Atrial Appendage Pacing for AF
This study tests two common atrial pacing methods to see which one is safer over 12 months for people getting a new pacemaker, ICD, or CRT device.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
-
Pace-and-ablate strategy in atrial fibrillation: who benefits and long-term outcomes
This study looks at adults with atrial fibrillation who underwent AV node ablation with permanent pacing to see who develops pacing-induced problems and how they do long-term.
-
AI-based cardiac analysis using 12-lead and 1-lead ECG
A clinician-facing pilot test to see if SmartECG-EF helps evaluate heart function using both 12-lead and single-lead ECGs in adults with heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.